ZUG, Switzerland–(BUSINESS WIRE)–Galderma, the leading company solely dedicated to advancing the future of dermatology, today premiered the positive phase III results from the OLYMPIA 2 trial…
AAD 2023: Late-Breaking Phase III Results Demonstrate nemolizumab』s Significant Impact on Prurigo Nodularis
ZUG, Switzerland–(BUSINESS WIRE)–Galderma, the leading company solely dedicated to advancing the future of dermatology, today premiered the positive phase III results from the OLYMPIA 2 trial…